State of New Jersey Common Pension Fund D maintained its position in Theravance Biopharma, Inc. (NASDAQ:TBPH) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 160,459 shares of the biopharmaceutical company’s stock at the end of the second quarter. State of New Jersey Common Pension Fund D’s holdings in Theravance Biopharma were worth $6,393,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TBPH. Legal & General Group Plc boosted its position in Theravance Biopharma by 11.6% in the first quarter. Legal & General Group Plc now owns 15,713 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 1,631 shares during the last quarter. Teachers Advisors LLC boosted its position in Theravance Biopharma by 15.2% in the first quarter. Teachers Advisors LLC now owns 80,113 shares of the biopharmaceutical company’s stock valued at $2,950,000 after buying an additional 10,550 shares during the last quarter. Harvest Management LLC bought a new position in Theravance Biopharma during the first quarter valued at approximately $228,000. Principal Financial Group Inc. bought a new position in Theravance Biopharma during the first quarter valued at approximately $420,000. Finally, American International Group Inc. boosted its position in Theravance Biopharma by 16.4% in the first quarter. American International Group Inc. now owns 24,276 shares of the biopharmaceutical company’s stock valued at $894,000 after buying an additional 3,417 shares during the last quarter. 84.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma, Inc. (TBPH) opened at 24.10 on Friday. The stock’s 50 day moving average price is $35.84 and its 200 day moving average price is $35.42. Theravance Biopharma, Inc. has a 52-week low of $23.15 and a 52-week high of $43.44. The firm’s market capitalization is $1.30 billion.

WARNING: “State of New Jersey Common Pension Fund D Has $6,393,000 Stake in Theravance Biopharma, Inc. (TBPH)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/13/state-of-new-jersey-common-pension-fund-d-has-6393000-stake-in-theravance-biopharma-inc-tbph.html.

Several research analysts recently commented on the company. BidaskClub raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Leerink Swann set a $47.00 target price on Theravance Biopharma and gave the stock a “buy” rating in a research note on Wednesday, May 10th. Needham & Company LLC boosted their target price on Theravance Biopharma from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, May 11th. ValuEngine raised Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the stock a “buy” rating in a research note on Wednesday, July 19th. Four equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Theravance Biopharma presently has an average rating of “Hold” and a consensus target price of $41.13.

In other Theravance Biopharma news, Director Henrietta Fore bought 6,000 shares of the stock in a transaction dated Friday, August 11th. The stock was bought at an average cost of $23.99 per share, for a total transaction of $143,940.00. Following the completion of the purchase, the director now directly owns 24,000 shares of the company’s stock, valued at $575,760. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Rick E. Winningham bought 10,000 shares of the stock in a transaction dated Friday, August 11th. The shares were acquired at an average price of $24.50 per share, with a total value of $245,000.00. Following the completion of the purchase, the chief executive officer now directly owns 866,377 shares of the company’s stock, valued at $21,226,236.50. The disclosure for this purchase can be found here. 6.10% of the stock is owned by company insiders.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.